These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28480166)

  • 21. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome and unmet needs in infantile-onset Pompe disease.
    Hahn A; Schänzer A
    Ann Transl Med; 2019 Jul; 7(13):283. PubMed ID: 31392195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
    Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
    Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa.
    Baek RC; Palmer R; Pomponio RJ; Lu Y; Ma X; McVie-Wylie AJ
    Mol Genet Metab Rep; 2016 Sep; 8():48-50. PubMed ID: 27489778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease.
    Koeberl DD; Case LE; Desai A; Smith EC; Walters C; Han SO; Thurberg BL; Young SP; Bali D; Kishnani PS
    Mol Genet Metab; 2020 Feb; 129(2):67-72. PubMed ID: 31839530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy.
    Colella P
    Mol Diagn Ther; 2024 Aug; ():. PubMed ID: 39134822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
    Winkler M; von Landenberg C; Kuchenbecker K; Reimann J; Kornblum C
    Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
    Yoshida T; Jonouchi T; Osafune K; Takita J; Sakurai H
    Front Cell Dev Biol; 2019; 7():316. PubMed ID: 31850350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.
    Al-Hassnan ZN; Khalifa OA; Bubshait DK; Tulbah S; Alkorashy M; Alzaidan H; Alowain M; Rahbeeni Z; Al-Sayed M
    Mol Genet Metab Rep; 2018 Jun; 15():50-54. PubMed ID: 30023291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
    Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
    Hsueh CY; Huang CY; Yang CF; Chang CC; Lin WS; Cheng HL; Wu SL; Cheng YF; Niu DM
    Orphanet J Rare Dis; 2021 Aug; 16(1):348. PubMed ID: 34353347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort.
    Pfrimmer C; Smitka M; Muschol N; Husain RA; Huemer M; Hennermann JB; Schuler R; Hahn A
    J Neuromuscul Dis; 2024; 11(1):167-177. PubMed ID: 38043017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of newborn screening for Pompe disease in Japan.
    Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
    Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical infantile-onset Pompe disease with good prognosis from mainland China: A case report.
    Zhang Y; Zhang C; Shu JB; Zhang F
    World J Clin Cases; 2022 Apr; 10(10):3278-3283. PubMed ID: 35603335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.
    Brassier A; Pichard S; Schiff M; Bouchereau J; Bérat CM; Caillaud C; Pion A; Khraiche D; Fauroux B; Oualha M; Barnerias C; Desguerre I; Hully M; Maquet M; Deladrière E; de Lonlay P; Gitiaux C
    Mol Genet Metab; 2023 Aug; 139(4):107650. PubMed ID: 37454519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.